Leptomeningeal Melanoma: A Patient Guide
At a Glance
Leptomeningeal melanoma occurs when melanoma cells spread into the fluid and membranes around the brain and spinal cord. Diagnosis usually combines contrast MRI of the brain and full spine with cerebrospinal fluid testing, while treatment is individualized.
Leptomeningeal disease (LMD), also known as leptomeningeal metastasis from melanoma, is a serious complication of advanced melanoma. It occurs when cancer cells enter the cerebrospinal fluid (CSF) and the thin, protective layers surrounding the brain and spinal cord known as the leptomeninges [1]. Because the CSF circulates, melanoma cells can travel through the fluid, creating a challenging tumor environment that is biologically distinct from the rest of the body [2].
While this diagnosis was historically associated with a very poor outlook, the introduction of modern therapies has begun to change the landscape of care. The focus has shifted toward individualized treatment strategies that aim to protect the nervous system and manage the patient’s quality of life [3].
What You Should Know Today
If you have just received this diagnosis, here are the core principles to keep in mind:
- Comprehensive Diagnostics Are Essential: Accurate management requires looking at the entire central nervous system. Doctors use contrast-enhanced MRI of both the brain and the full spine, alongside detailed analysis of the CSF, to identify where the cancer has settled [4].
- Watch for Neurological Symptoms: Melanoma in the fluid can cause multifocal symptoms—issues occurring in different parts of the body simultaneously, such as a severe headache paired with leg weakness or double vision [5]. Call your oncology team promptly for any new neurological changes, and call 911 for severe emergencies like seizures, acute paralysis, or loss of bowel/bladder control.
- Treatment is Highly Individualized: There is no single “standard” treatment path. Based on your symptoms, tumor genetics, and overall health, your team may consider systemic dual immunotherapies, targeted BRAF/MEK inhibitors, radiation, or clinical trials [6][7]. Durable control occurs in select patients, though it is not guaranteed.
- You Need a Multidisciplinary Team: Because the condition can cause physical complications like hydrocephalus (fluid buildup), a team including neuro-oncologists, neurosurgeons, palliative care specialists, and radiation oncologists is essential to manage both the cancer and the symptoms that impact your daily function [8].
Living with leptomeningeal metastasis involves a careful balance of disease-directed treatment and supportive care. By working closely with a specialized team, you can develop a plan that reflects your personal goals and addresses the unique challenges of this condition [9].
In this guide
5 chapters
Understanding Melanoma in the Leptomeninges
Learn about leptomeningeal melanoma: how it spreads through cerebrospinal fluid, prognosis, treatment options, supportive care, and questions for the care team.
Recognizing Symptoms and Emergency Signs
Learn to recognize leptomeningeal melanoma symptoms, including headache, weakness, vision changes, seizures, and signs that require urgent oncology help or 911.
Navigating the Diagnostic Process
Learn how leptomeningeal melanoma is diagnosed with brain and spine MRI, lumbar puncture, CSF cytology, and advanced DNA and cell tests when appropriate.
Treatment Options and Personalized Care
Learn how leptomeningeal melanoma is treated with immunotherapy, BRAF/MEK targeted therapy, radiation, intrathecal therapy, supportive care, and clinical trials.
Your Care Team and Quality of Life
Learn how melanoma-associated leptomeningeal disease care teams manage symptoms, hydrocephalus, performance status, treatment choices, and quality of life.
Common questions in this guide
What is leptomeningeal melanoma?
What tests are used to diagnose leptomeningeal melanoma?
Which neurological symptoms should I report to my care team?
How is leptomeningeal melanoma treated?
Can leptomeningeal melanoma cause hydrocephalus?
Which specialists should be involved in my care?
Get notified when new evidence is published on leptomeningeal melanoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (9)
- 1
[Spinal metastases combined with leptomeningeal metastasis: A case report].
Ma LJ, Hu PP, Liu XG
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2023; (55(3)):563-566.
PMID: 37291936 - 2
Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases.
Khaled ML, Tarhini AA, Forsyth PA, et al.
Cancers 2023; (15(6)) doi:10.3390/cancers15061884.
PMID: 36980770 - 3
Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).
Ferguson SD, Bindal S, Bassett RL, et al.
Journal of neuro-oncology 2019; (142(3)):499-509 doi:10.1007/s11060-019-03121-2.
PMID: 30847840 - 4
Cerebrospinal Fluid Dissemination and Neoplastic Meningitis in Primary Brain Tumors.
Chowdhary S, Damlo S, Chamberlain MC
Cancer control : journal of the Moffitt Cancer Center 2017; (24(1)):S1-S16 doi:10.1177/107327481702400118.
PMID: 28557973 - 5
Pathophysiology and treatment of leptomeningeal metastases in lung cancer.
Hida T
Translational lung cancer research 2026; (15(1)):19 doi:10.21037/tlcr-2025-aw-1247.
PMID: 41659263 - 6
Melanoma brain metastases - Interdisciplinary management recommendations 2020.
Gutzmer R, Vordermark D, Hassel JC, et al.
Cancer treatment reviews 2020; (89()):102083 doi:10.1016/j.ctrv.2020.102083.
PMID: 32736188 - 7
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
Glitza Oliva IC, Ferguson SD, Bassett R, et al.
Nature medicine 2023; (29(4)):898-905 doi:10.1038/s41591-022-02170-x.
PMID: 36997799 - 8
Surgical Treatment for Leptomeningeal Disease.
Volkov AA, Filis AK, Vrionis FD
Cancer control : journal of the Moffitt Cancer Center 2017; (24(1)):47-53 doi:10.1177/107327481702400107.
PMID: 28178712 - 9
Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.
Wilcox JA, Chukwueke UN, Ahn MJ, et al.
Neuro-oncology 2024; (26(10)):1781-1804 doi:10.1093/neuonc/noae103.
PMID: 38902944
This page is for informational purposes only and does not constitute medical advice. Your oncology and neuro-oncology teams should interpret your symptoms and test results and discuss treatment choices for your situation.